THE JOURNAL OF MUNDANE BEHAVIORBusiness Directories,Company Directories

Company Name: Corporate Name:	THE JOURNAL OF MUNDANE BEHAVIOR
Company Title:
Company Description:
Keywords to Search:
Company Address:	PO Box 365,MENLO PARK,CA,USA
ZIP Code: Postal Code:	92833
Telephone Number:	6262965561 (+1-626-296-5561)
Fax Number:
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	731304
USA SIC Description:	Media Brokers
Number of Employees:
Sales Amount:
Credit History: Credit Report:
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
MAGELANG INSTITUTE LLC
REIKI CLINIC
N/A

Next company profile:
INTERWEST PARTNERS
ALMANAC
PRIMECORE PROPERTIES; INC.

Company News:

The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
Medical Specialties | The New England Journal of Medicine
Featuring articles on topics such as leukemia, breast cancer, colon cancer, mammograms, colonoscopy, occult-blood screening, stem cell and bone marrow transplantation, radiation, and chemotherapy
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα
Lorundrostat Efficacy and Safety in Patients with Uncontrolled . . .
Background Aldosterone dysregulation contributes to hypertension Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream . . .
Bloodstream infections are associated with substantial morbidity and mortality Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain In a multicenter, non
Tirzepatide for Heart Failure with Preserved Ejection Fraction and . . .
Obesity increases the risk of heart failure with preserved ejection fraction Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Methods In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
Base editors can correct disease-causing genetic variants After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated 50% mortality